INSM vs. LEGN, ARNA, FTSV, CCXI, TGTX, TAK, ALNY, TEVA, GMAB, and RPRX
Should you be buying Insmed stock or one of its competitors? The main competitors of Insmed include Legend Biotech (LEGN), Arena Pharmaceuticals (ARNA), Forty Seven (FTSV), ChemoCentryx (CCXI), TG Therapeutics (TGTX), Takeda Pharmaceutical (TAK), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), and Royalty Pharma (RPRX).
Legend Biotech (NASDAQ:LEGN) and Insmed (NASDAQ:INSM) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, community ranking, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.
Legend Biotech has higher earnings, but lower revenue than Insmed. Legend Biotech is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.
Legend Biotech presently has a consensus target price of $81.31, suggesting a potential upside of 43.64%. Insmed has a consensus target price of $74.50, suggesting a potential downside of 0.05%. Given Insmed's higher possible upside, analysts clearly believe Legend Biotech is more favorable than Insmed.
70.9% of Legend Biotech shares are held by institutional investors. 0.0% of Legend Biotech shares are held by insiders. Comparatively, 4.6% of Insmed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Legend Biotech has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500. Comparatively, Insmed has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500.
In the previous week, Legend Biotech had 3 more articles in the media than Insmed. MarketBeat recorded 10 mentions for Legend Biotech and 7 mentions for Insmed. Legend Biotech's average media sentiment score of 0.83 beat Insmed's score of 0.59 indicating that Insmed is being referred to more favorably in the news media.
Insmed received 459 more outperform votes than Legend Biotech when rated by MarketBeat users. However, 67.96% of users gave Legend Biotech an outperform vote while only 65.80% of users gave Insmed an outperform vote.
Legend Biotech has a net margin of -135.92% compared to Legend Biotech's net margin of -236.74%. Legend Biotech's return on equity of 0.00% beat Insmed's return on equity.
Summary
Insmed beats Legend Biotech on 9 of the 17 factors compared between the two stocks.
Get Insmed News Delivered to You Automatically
Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
